1/16
08:45 am
vnrx
Volition Sponsors Symposium at Veterinary Meeting and Expo
Medium
Report
Volition Sponsors Symposium at Veterinary Meeting and Expo
1/9
08:02 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
1/8
09:23 am
vnrx
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats [Yahoo! Finance]
Low
Report
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats [Yahoo! Finance]
1/8
09:15 am
vnrx
VolitionRx Secures $2.0 Million in Funding
Medium
Report
VolitionRx Secures $2.0 Million in Funding
1/8
08:45 am
vnrx
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
Medium
Report
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
12/18
08:05 am
vnrx
VolitionRx (NYSE:VNRX) had its price target lowered by analysts at D. Boral Capital from $5.00 to $3.00. They now have a "buy" rating on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its price target lowered by analysts at D. Boral Capital from $5.00 to $3.00. They now have a "buy" rating on the stock.
12/17
08:45 am
vnrx
Volition Issues Business Review 2025
Low
Report
Volition Issues Business Review 2025
12/11
09:00 am
vnrx
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
Low
Report
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
12/8
09:00 am
vnrx
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
Low
Report
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
12/4
01:28 pm
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
12/4
09:00 am
vnrx
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
Medium
Report
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
12/3
02:19 pm
vnrx
VolitionRx (NYSE:VNRX) had its "hold" rating reaffirmed by analysts at Maxim Group.
Low
Report
VolitionRx (NYSE:VNRX) had its "hold" rating reaffirmed by analysts at Maxim Group.
11/26
12:56 pm
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
11/25
09:10 am
vnrx
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use [Yahoo! Finance]
Low
Report
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use [Yahoo! Finance]
11/25
08:45 am
vnrx
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
High
Report
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
11/17
12:01 pm
vnrx
VolitionRx (NYSE:VNRX) had its price target lowered by analysts at HC Wainwright from $2.50 to $1.50. They now have a "buy" rating on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its price target lowered by analysts at HC Wainwright from $2.50 to $1.50. They now have a "buy" rating on the stock.
11/17
08:20 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Medium
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
11/14
12:54 pm
vnrx
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/10
08:45 am
vnrx
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
Low
Report
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update